Spots Global Cancer Trial Database for ralimetinib (ly2228820 dimesylate)
Every month we try and update this database with for ralimetinib (ly2228820 dimesylate) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors | NCT02322853 | Postmenopausal Metastatic Brea... | Tamoxifen Ralimetinib (LY... | 18 Years - | Centre Francois Baclesse |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
